Top Authors

• Most frequent coverage on DNDN

• 
  Mike Huckman (225 followers)

  • Why Did Dendreon Execs Cash Out on Friday? (Tue, May 5)
  • Biotech Analyst Eats Dendreon's Provenge Crow (Thu, Apr 16)
  • Dendreon: Freaky Friday (Fri, Apr 3)

  More by Mike Huckman on DNDN »
• 
  SA Editor Miriam Metzinger (531 followers)

  • Cramer's Mad Money - Hey Big Spenders (11/5/09) (Fri, Nov 6)
  • Cramer's Lightning Round - Dendreon Is Real (7/7/09) (Wed, Jul 8)
  • Cramer's Lightning Round - Mindshare Is Going Towards Bing (6/22/09) (Tue, Jun 23)

  More by SA Editor Miriam Metzinger on DNDN »
• 
  Mike Havrilla (1924 followers)

  • BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte (Fri, Sep 25)
  • Tracking Healthcare Trends and More (Wed, Aug 5)
  • Access Pharma: A Smallcap Cancer Biotech Call Option Trade (Thu, May 28)

  More by Mike Havrilla on DNDN »

• Most followed authors on DNDN

• 
  TraderMark (3729 followers)

  • Best Performing Stocks of the Last Quarter (Mon, Jun 15)
  • A Chance to Get Back in the Market (Tue, Apr 28)

  More by TraderMark on DNDN »
• 
  Bespoke Investment Group (3504 followers)

  • Best Performing Stocks Since 3/9/09 and 10/9/07 (Thu, Nov 12)
  • The Top 25 (Thu, Oct 1)
  • Russell 3,000 Stocks Up More than 200% Year to Date (Sun, Jun 28)

  More by Bespoke Investment Group on DNDN »
• 
  SA Editor Rachael Granby (2020 followers)

  • Wall Street Breakfast: Must-Know News (Wed, Apr 29)

  More by SA Editor Rachael Granby on DNDN »

• Newest authors on DNDN

• 
  Matthew Goldstein (75 followers)

  • SEC Shouldn't Rest on Flash Trading Ban (Fri, Sep 18)

  More by Matthew Goldstein on DNDN »
• 
  Justin M. Hall (672 followers)

  • Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers (Sun, Sep 20)
  • Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up (Fri, Sep 11)

  More by Justin M. Hall on DNDN »
• 
  Beacon Asset Managers (130 followers)

  • Dendreon: Charting the Course to Big Profits (Wed, Jun 10)

  More by Beacon Asset Managers on DNDN »

• Most commented on DNDN

• 
  Michael Murphy (527 followers)

  • A Biotech Triple Play: Dendreon, BioCryst and Arena (Mon, May 25)
  • Is Dendreon a $360 Stock - Or Is That Too Low? (Wed, Apr 22)

  More by Michael Murphy on DNDN »
• 
  Mike Huckman (225 followers)

  • Why Did Dendreon Execs Cash Out on Friday? (Tue, May 5)
  • Biotech Analyst Eats Dendreon's Provenge Crow (Thu, Apr 16)
  • Dendreon: Freaky Friday (Fri, Apr 3)

  More by Mike Huckman on DNDN »
• 
  Theodore Cohen (2 followers)

  • Dendreon's Provenge: Government Agencies Play Hide and Seek With Facts (Thu, Jun 12)
  • Dendreon: The Provenge Approval Scandal, One Year Later (Wed, May 7)
  • Dendreon: The FDA's Commissioner Doth Protest Too Much! (Mon, Apr 21)

  More by Theodore Cohen on DNDN »